What question did this study set out to answer?

To determine the contributions of CTLA-4 blockade on effector and regulatory T cell compartments in cancer therapy.

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates CTLA-4 blockade effects on tumor responses in mouse models, suggesting dual targeting enhances antitumor efficacy.

To determine the contributions of CTLA-4 blockade on effector and regulatory T cell compartments in cancer therapy.
Developed a mouse model expressing human CTLA-4 to investigate its blockade.
Evaluated tumor responses in vivo in a mouse melanoma model with various blockade strategies.
Blockade on effector T cells led to significant improvement in tumor protection.
Blockade on regulatory T cells alone failed to enhance antitumor responses.
Concomitant blockade of both compartments resulted in synergistic effects and maximum antitumor activity.

Peggs et al. (2009) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial evaluates CTLA-4 blockade effects on tumor responses in mouse models, suggesting dual targeting enhances antitumor efficacy.